Drug Trial Radar · NCT03655613
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Last checked: Nov 19, 2026Latest source record: May 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
20
Actual
Start
Sep 5, 2018
Primary completion
Dec 15, 2021
Study completion Dec 15, 2021
Sponsor
- Lead sponsor
- Apollomics (Australia) Pty. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.); Novotech (Australia) Pty Limited
- First posted
- Aug 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Design and Investigational Plan: This is an open-label Phase 1/2 study to assess the safety and tolerability of combination PD-1 inhibitor (APL-501 or nivolumab) administered concomitantly with c-Met inhibitor (APL-101), to determine the recommended Phase 2 dose of the combination, and to obtain preliminary efficacy in HCC or RCC subjects with advanced or metastatic disease that have not been previously treated with a PD 1 inhibitor or a c-Met inhibitor. HCC subjects will receive the combination APL-501 plus APL-101 while RCC subjects will receive the combination nivolumab plus APL-101. In Phase 1, mandatory archival or fresh tumor biopsies will be collected. In Phase 2, a mandatory fresh tumor biopsy will be required for study entry and another fresh biopsy will be collected between Cycles 2 and 4. The frequency of administration of PD-1 inhibitors will be every 2 weeks starting in Cycle 1 on Day 8 and Day 22 of a 35-day cycle with all subsequent cycles on Day 1 and Day 15 of 28-day cycles. APL-101 will be administered orally every 12 hours continuously on an empty stomach.
Conditions
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
Interventions
APL-501Biological
Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
APL-101Drug
Oral specific c-Met inhibitor
NivolumabBiological
Fully human IgG4 monoclonal antibody against PD-1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (Phase 1)Time frame: Cycle 1 (up to 35 days)
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
Border Medical Oncology Research Unit
Albury, New South Wales, Australia
Macquarie University
Sydney, New South Wales, Australia
Crown Princess Mary Cancer Centre
Westmead, New South Whales, Australia
Ashford Cancer Center
Adelaide, South Australia, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Sunshine Hospital
Saint Albans, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Afffinity Clinical Research
Perth, Western Australia, Australia
Auckland City Hospital
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.